drugset / Trial / NCT02494804
Effect of Cytokine-induced Killer Cells for Stage I-II Malignant Gliomas
Non-randomizedParallel-groupOpen-label
Summary
The purpose of this study is to determine whether combining of Temozolomide and cytokine-induced killer cells (CIK) transfusion can prolong survival of patients with Malignant Gliomas. The effectiveness and safety of CIK cells for the treatment of Malignant Glioma is also evaluated.
Timeline
- Start
- 2015-07
- Primary completion
- 2028-07
- Completion
- 2030-07
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Temozolomide | Small molecule | 200 mg/m2 | — |
| Subject | cytokine-induced killer cells | Cell therapy | — | Intravenous |